Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
CABOTEGRAVIR IS A LONG-ACTING, INJECTABLE HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) INTEGRASE STRAND TRANSFER INHIBITOR THAT HAS BEEN STUDIED FOR PrEP.
Pre-Exposure Prophylaxis (PrEP) is the use of medicine taken before HIV exposure to help prevent HIV infection. Cabotegravir LA is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test prior to initiating cabotegravir for HIV-1 PrEP.
Registrational
Trials
Clinical data from the HPTN 083 and 084 registrational trials
Medical
Information
Medical information resource for product questions about cabotegravir LA for PrEP
HIV Prevention
Tools
Information on HIV prevention tools such as PrEP, TasP, PEP, and more
